Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

37.59
+0.66001.79%
Volume:1.44M
Turnover:54.08M
Market Cap:43.79B
PE:62.65
High:37.85
Open:37.15
Low:37.12
Close:36.93
52wk High:37.85
52wk Low:17.82
Shares:1.17B
Float Shares:1.09B
Volume Ratio:0.56
T/O Rate:0.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6000
EPS(LYR):1.21
ROE:9.69%
ROA:5.13%
PB:5.65
PE(LYR):31.07

Loading ...

Teva Pharmaceutical Industries (TEVA) Could Be 10% Undervalued After FDA Accepted Ecopipam NDA

Simply Wall St.
·
Yesterday

Teva (TEVA) Wins FDA Priority Review For Pediatric Tourette Drug Candidate

Simply Wall St.
·
Aug 20

TEVA Stock Climbs as 50-Year-Long Tourette Syndrome Drug Breakthrough Moves Closer

TIPRANKS
·
Aug 19

Teva Pharmaceuticals Says FDA Accepts Ecopipam Filing for Tourette Syndrome

MT Newswires Live
·
Aug 19

Teva price target raised to $42 from $40 at Barclays

TIPRANKS
·
Aug 17

Teva Pharmaceuticals Price Target Raised to $42.00/Share from $40.00 by Barclays

Dow Jones
·
Aug 12

Teva Seeks to Keep Israel Ties from Jury, Cites Gaza War

Reuters
·
Aug 07

July 2026's Top Stock Selections Estimated Below Intrinsic Value

Simply Wall St.
·
Jul 31

Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST), Teva Pharmaceutical (TEVA) and MannKind (MNKD)

TIPRANKS
·
Jul 30

Stocks to Watch Recap: Ford, Caterpillar, Teva, Starbucks

Dow Jones
·
Jul 30

Teva's Innovative Drug Portfolio Fuels Growth as Company Raises Outlook, Transitions to Direct NYSE Listing

Benzinga Earnings
·
Jul 30

Movement Alert|Teva Pharmaceutical Rises 6.95% in Regular Trading, Q2 Revenue Beats Expectations and Full-Year Guidance Raised

Market Focus
·
Jul 29

Stock Track | Teva Pharmaceutical Soars 6.47% Intraday on Q2 Revenue Beat and Raised Sales Outlook

Stock Track
·
Jul 29

Teva Pharmaceutical Industries Q2 Adjusted Earnings, Revenue Fall; Raises 2026 Revenue Guidance

MT Newswires Live
·
Jul 29

Teva Pharmaceutical Industries Limited.. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 29

Teva Lifts Sales View as Brand-Name Business Gains Traction

Dow Jones
·
Jul 29

Stock Track | Teva Pharmaceutical Soars 5.15% in Pre-Market Trading on Q2 Revenue Beat and Guidance

Stock Track
·
Jul 29

Movement Alert|Teva Pharmaceutical Rises 5.15% in Pre-Market Trading, Q2 Revenue Beats Expectations Despite Significant EPS Miss

Market Focus
·
Jul 29

GUIDANCE: (TEVA) Teva Pharmaceutical Expects 2026 Revenue Range $16.5B - $16.85B

MT Newswires Live
·
Jul 29

Teva Pharmaceutical Indus Q2 Adj. EPS $0.02 Misses $0.25 Estimate, Sales $4.142B Beat $4.047B Estimate

Benzinga Earnings
·
Jul 29